Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Bone Marrow Ablation"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mirsaeed Nikzad, Amir Reza Jalilian, Simindokht Shirvani-Arani, Ali Bahrami Samani, Hamid Golchobian
Publikováno v:
Pharmaceutical and Biomedical Research, Vol 2, Iss 1, Pp 14-22 (2016)
In this study, production, quality control and biodistribution studies of 166Ho-zoledronate have been presented as a possible bone marrow ablative agent. Ho-166 chloride was produced by thermal neutron irradiation of natural 165Ho(NO3)3 samples. 166H
Externí odkaz:
https://doaj.org/article/1eac012274234363a4320ad88ecad125
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kae Kakura, Hirofumi Kido, Kiyono Koi, Hiroki Fujimoto, Yoko Miyazaki-Asato, Tsukasa Yanagi, Junro Yamashita
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Bone marrow ablation prompts transient bone formation in nearly the entire medullary cavity before marrow regeneration occurs. Here, we establish a procedure to direct bone formation in a desired particular site within the medullary cavity for suppor
Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy
Publikováno v:
Journal of Radiotherapy in Practice. 18:70-74
AimBone-seeking radiopharmaceuticals are potential therapeutic tools for bone marrow ablation in patients with multiple myeloma. In this procedure, estimation of radiation absorbed dose received by the target and non-target organs is one of the most
Autor:
Mohsen Mehrabi, Mohammad Ghannadi Maraghe, Simindokht Shirvani Arani, Ali Bahrami Samani, Nafise Salek, Sara Vosoghi
Publikováno v:
Current Radiopharmaceuticals. 11:116-122
Background and objective Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow. Methods In this research, carrier-free (c.f.) 90
Autor:
Tetsuo Nakabayashi, Guangwen Jin, Shingo Sato, Zulipiya Aibibula, Jinying Piao, Kunikazu Tsuji, Daisuke Koga, Toshio Miyata, Hiroki Ochi, Alkebaier Aobulikasimu, Atsushi Okawa, Yoshinori Asou
Publikováno v:
FEBS Open Bio
Osteoporosis is a progressive bone disease caused by an imbalance between bone resorption and formation. Recently, plasminogen activator inhibitor-1 (PAI-1) was shown to play an important role in bone metabolism using PAI-1-deficient mice. In this st
Autor:
Michael S. Pepper, I M Viljoen
Publikováno v:
South African Medical Journal. 111:1055
The discovery of human leucocyte antigen (HLA), serological matching and HLA-typing techniques, combined with the development of immunosuppressive medicines and improvements in infection control, have opened the way to cell, tissue and vascularised o
Publikováno v:
Radiation Physics and Chemistry. 187:109560
Bone marrow malignancies including multiple myeloma are treated by the myeloablative radiotherapy and subsequent stem cell transplantation. Radiopharmaceuticals are used for the selective delivery of radiation absorbed dose to bone marrow. In this wo
Autor:
Lin Chen, Xiaoling Xu, Junlan Huang, Nan Su, Quan Wang, Liang Chen, Min Jin, Zuqiang Wang, Yu Gao, Xiaolan Du, Fengtao Luo, Chu-Xia Deng, Liang Kuang, Huabing Qi, Wei Xu, Hangang Chen, Yangli Xie, Shuai Chen, Wanling Jiang, Xianding Sun, Bo Chen, Qiaoyan Tan, Siru Zhou, Ying Zhu
Publikováno v:
Journal of Bone and Mineral Research. 32:2194-2206
Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2). Previous studies have shown that gain-of-function mutations of FGFR2 (S252W or P253R) cause skull mal